# Yescarta (axicabtagene ciloleucel) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/axicabtagene-ciloleucel

> The next catalyst for Yescarta (axicabtagene ciloleucel), sponsored by GILEAD SCIENCES, INC. (GILD), is its primary completion, October 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Yescarta (axicabtagene ciloleucel) |
| Codes |  |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications | [Relapsed or Refractory Large B-cell Lymphoma](https://sec-api.dev/indications/relapsed-or-refractory-large-b-cell-lymphoma), [Relapsed/Refractory Follicular Lymphoma](https://sec-api.dev/indications/relapsed-refractory-follicular-lymphoma) |
| Modality | cell_therapy |
| FDA designations | none disclosed |

## Timeline

### November 24, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Relapsed or Refractory Large B-cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05459571 (Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-11-12." https://clinicaltrials.gov/study/NCT05459571

### Feb 2026: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2026-05-06, last confirmed 2026-05-06.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-031269): "•In February 2026, patient dosing commenced in PiNACLE-H2H, the first-of-its-kind Phase 3 randomized controlled trial evaluating ronde-cel versus investigator's choice of axicabtagene ciloleucel or lisocabtagene maraleucel in patients with R/R LBCL in the 2L setting." https://www.sec.gov/Archives/edgar/data/1806952/000162828026031269/lyel-20260506x8kexx991.htm

### November 12, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Relapsed or Refractory Large B-cell Lymphoma.
- First seen 2026-11-12T15:32:36.529Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05459571 (Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-11-12." https://clinicaltrials.gov/study/NCT05459571?tab=results

### October 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Relapsed/Refractory Follicular Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05371093 (Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." https://clinicaltrials.gov/study/NCT05371093

### Oct 2030 to Jan 2031: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Relapsed/Refractory Follicular Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05371093 (Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." https://clinicaltrials.gov/study/NCT05371093

## Same indication

- [BRUKINSA® (zanubrutinib)](https://sec-api.dev/pdufa/zanubrutinib) (ONC)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/axicabtagene-ciloleucel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Yescarta (axicabtagene ciloleucel) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/axicabtagene-ciloleucel

```bibtex
@misc{secapidev_pdufa_axicabtagene_ciloleucel_20261116,
  title        = {Yescarta (axicabtagene ciloleucel) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/axicabtagene-ciloleucel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_axicabtagene_ciloleucel_20261116","title":"Yescarta (axicabtagene ciloleucel) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/axicabtagene-ciloleucel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
